Clinical research organisation (CRO) Celerion has been recognised for its contributions to the industry by claiming an award for the seventh consecutive year.
The company was named recipient of the Life Science Leader and Clinical Leader’s CRO Leadership Awards in all five award categories. The awards recognise the CRO in five categories: capabilities, compatibility, expertise, quality, and reliability in meeting the needs of big and small pharmaceutical clients alike.
“We are of course honoured again for such comprehensive recognition,” said Celerion CEO Susan Thornton,“This award validates the many things we do to enable clients to bring drugs quickly to market, bettering the lives of people in need around the world. It’s gratifying that our commitment to excellence is noted by this pillar of our industry,” she added.
“Industry Standard Research continues to consider it an honour to provide the primary market research data for Life Science Leader and Clinical Leader’s CRO Leadership Awards. ISR’s stringent screening process ensures that only highly qualified industry decision-makers participate in our CRO benchmarking market research. This is paramount as we ask the research participants to provide experiential, not perceptual, feedback on their involvement with contract suppliers over the past 18 months,” said Kevin Olson, CEO of Industry Standard Research.